Evaluation of anti-leishmanial activity of artemisinin combined with amphotericin B or miltefosine in Leishmania donovani promastigotes

Musfikur Rahaman, Susmita Ghosh, Lopamudra Dhar Chowdhury, Mitali Chatterjee

Abstract


Background: The increasing incidence of drug resistance in Leishmaniasis necessitates evaluation of combination chemotherapy. Miltefosine and amphotericin B are established anti-leishmanial drugs, while artemisinin has shown significant leishmanicidal activity in experimental models. In this study, we have evaluated the additive/synergistic effect of artemisinin with amphotericin B or miltefosine.

Methods: Leishmania parasites were isolated from the bone marrow aspirate of a patient with visceral leishmaniasis. Parasites were typed as Leishmania donovani by restriction fragment length polymorphism of internal transcribed spacer 1 region of Leishmania genome. Promastigotes were incubated in a fixed ratio combination of artemisinin (0-500 µM) and amphotericin B (0-100 nM) or miltefosine (0-100 µM) and cell viability was assessed. An isobologram was constructed to evaluate the additive/synergistic effect, wherein it was considered additive if the mean sum fractional inhibitory concentration (mean ΣFIC) at the IC50 level was <2, but ≥1 and synergism, if the mean ΣFIC was <1.

Results: The isobologram showed an additive effect for three combinations of artemisinin-amphotericin B and artemisinin-miltefosine, the mean ΣFICs ranging from 1.02 to 1.44 and 1.08 to 1.33 along with a synergistic effect with one combination, the mean ΣFICs being 0.58 and 0.81 respectively.

Conclusions: This study supports the combination use of artemisinin-amphotericin B and artemisinin-miltefosine, worthy of future pharmacological consideration.


Keywords


Antileishmanial activity, Artemisinin, Amphotericin B, Miltefosine, Promastigotes

Full Text:

PDF

References


World Health Organization (WHO), 2009. Leishmaniasis: the global trend. Available from: http://www.who.int/neglected_diseases/integrated_media_leishmaniasis/en/index.html. [Last accessed on 2014 Jul 7].

World Health Organization (WHO), 2009. Leishmaniasis: burden of disease. Available from: http://www.who.int/leishmaniasis/burden/en/. [Last accessed on 2014 Jul 7].

Baranwal AK, Mandal RN, Singh R, Singhi SC. Sodium stibogluconate and polymorphic ventricular tachycardia. Indian J Pediatr. 2005;72(3):269.

Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res. 2006;123(3):345-52.

Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res. 2006;123(3):399-410.

Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother. 2006;50(1):73-9.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477-86.

Fauci AS, Braunwald E, Isselbacher KJ, Kasper DL, Hauser SL, Longo DL, et al., editors. Harrison’s Principles of Internal Medicine. 17th Edition. New York: McGraw Hill, Health Professions Division; 2008.

World Health Organization (WHO), 2010. Guidelines for the Treatment of Malaria. Available from: http://www.who.int/malaria/docs/ [Last accessed on 2014 Jul 7].

Sen R, Bandyopadhyay S, Dutta A, Mandal G, Ganguly S, Saha P, et al. Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol 2007;56 Pt 9:1213-8.

Sen R, Ganguly S, Saha P, Chatterjee M. Efficacy of artemisinin in experimental visceral leishmaniasis. Int J Antimicrob Agents. 2010;36(1):43-9.

Yang DM, Liew FY. Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. Parasitology. 1993;106 Pt 1:7-11.

Das NK, Singh SK, Ghosh S, Sarkar A, Mukhopadhyay D, Roy S, et al. Case series of misdiagnosis with rK39 strip test in Indian leishmaniasis. Am J Trop Med Hyg. 2011;84(5):688-91.

Ghosh S, Banerjee P, Sarkar A, Datta S, Chatterjee M. Coinfection of Leptomonas seymouri and Leishmania donovani in Indian leishmaniasis. J Clin Microbiol 2012;50(8):2774-8.

Ganguly S, Bandyopadhyay S, Sarkar A, Chatterjee M. Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. J Microbiol Methods. 2006;66(1):79-86.

Bhattacharya A, Mishra LC, Bhasin VK. In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum. Am J Trop Med Hyg. 2008;78(5):721-8.

Gupta S, Thapar MM, Wernsdorfer WH, Björkman A. In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother. 2002;46(5):1510-5.

Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006;319(1):

-7.

Sarkar A, Saha P, Mandal G, Mukhopadhyay D, Roy S, Singh SK, et al. Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis. Cytometry A. 2011;79(1):35-45.